A Pill for Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, while effective, are often hindered by poor patient adherence due to discomfort and lifestyle disruption. In response to this unmet need, Apnimed’s novel investigational therapy, AD109, offers a compelling oral alternative for OSA. AD109 is a combination of atomoxetine, a norepinephrine reuptake…